SG11201501623PA - Recombinant particle based vaccines against human cytomegalovirus infection - Google Patents
Recombinant particle based vaccines against human cytomegalovirus infectionInfo
- Publication number
- SG11201501623PA SG11201501623PA SG11201501623PA SG11201501623PA SG11201501623PA SG 11201501623P A SG11201501623P A SG 11201501623PA SG 11201501623P A SG11201501623P A SG 11201501623PA SG 11201501623P A SG11201501623P A SG 11201501623PA SG 11201501623P A SG11201501623P A SG 11201501623PA
- Authority
- SG
- Singapore
- Prior art keywords
- against human
- human cytomegalovirus
- vaccines against
- based vaccines
- particle based
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190652 | 2012-10-30 | ||
| PCT/EP2013/072717 WO2014068001A1 (en) | 2012-10-30 | 2013-10-30 | Recombinant particle based vaccines against human cytomegalovirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501623PA true SG11201501623PA (en) | 2015-05-28 |
Family
ID=47073362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501623PA SG11201501623PA (en) | 2012-10-30 | 2013-10-30 | Recombinant particle based vaccines against human cytomegalovirus infection |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150359879A1 (en) |
| EP (2) | EP3269388A1 (en) |
| JP (1) | JP6294890B2 (en) |
| KR (1) | KR20150076244A (en) |
| CN (1) | CN104853772A (en) |
| AU (1) | AU2013340820A1 (en) |
| BR (1) | BR112015008930A2 (en) |
| CA (1) | CA2885145A1 (en) |
| ES (1) | ES2608637T3 (en) |
| HK (1) | HK1213185A1 (en) |
| IL (1) | IL237793A0 (en) |
| MX (1) | MX2015005505A (en) |
| PH (1) | PH12015500931A1 (en) |
| RU (1) | RU2015121828A (en) |
| SG (1) | SG11201501623PA (en) |
| WO (1) | WO2014068001A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3134117A1 (en) * | 2014-04-23 | 2017-03-01 | Institute for Research in Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| TW201609792A (en) * | 2014-05-08 | 2016-03-16 | 輝瑞大藥廠 | Means and methods for treating CMV |
| US10428118B2 (en) * | 2014-07-16 | 2019-10-01 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| US10010607B2 (en) | 2014-09-16 | 2018-07-03 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response |
| EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP3770265B1 (en) | 2016-03-16 | 2023-10-11 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer |
| AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP3573649A4 (en) * | 2017-01-27 | 2020-12-30 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| CA3060019A1 (en) | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| US11524069B2 (en) * | 2017-09-13 | 2022-12-13 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
| FR3077490B1 (en) * | 2018-02-02 | 2022-11-11 | Univ Franche Comte | NEW VACCINE COMPOSITIONS FOR FIGHT AGAINST BREAST CANCER, AND METHOD FOR PREPARATION |
| EP3762025A4 (en) * | 2018-03-09 | 2021-12-01 | The Regents of the University of California | Cmv vectors and uses thereof |
| WO2019216929A1 (en) * | 2018-05-11 | 2019-11-14 | City Of Hope | Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof |
| KR102018341B1 (en) * | 2018-06-21 | 2019-09-04 | 성균관대학교산학협력단 | A pharmaceutical composition for preventing or treating cancer comprising RNF170 and pUL50 as an active ingredient |
| CA3116175A1 (en) | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US20230266320A1 (en) * | 2019-11-26 | 2023-08-24 | Merck Sharp & Dohme Llc | Method for detecting cytomegalovirus (cmv) and measuring and quantifying pentameric complex using an indirect sandwich elisa |
| TWI810589B (en) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | Human cytomegalovirus gb polypeptide |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2023223255A1 (en) | 2022-05-20 | 2023-11-23 | Glaxosmithkline Biologicals Sa | Modified varicella zoster virus glycoprotein e proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990085A (en) | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
| BRPI0512042B8 (en) | 2004-06-16 | 2021-05-25 | Glaxosmithkline Biologicals Sa | immunogenic composition, vaccine, use of a composition or vaccine, method for producing an immunogenic composition, and, use of vlps or capsomeres of hpv 16 and 18 with vlps or capsomeres of at least one other hpv of the cancer-causing type |
| CA2682700A1 (en) * | 2007-05-11 | 2008-11-20 | Vakzine Projekt Management Gmbh | Composition containing hcmv particles |
| EP2303319B1 (en) * | 2008-06-20 | 2016-10-05 | Duke University | Compositions, methods and kits for eliciting an immune response |
| CA2760524C (en) * | 2009-05-01 | 2017-09-12 | Redbiotec Ag | Recombinant virus-like particles encoded by multi-gene vector |
| GB0907935D0 (en) * | 2009-05-08 | 2009-06-24 | Henderson Morley Plc | Vaccines |
| ES2656050T3 (en) * | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| KR102301463B1 (en) * | 2011-11-11 | 2021-09-14 | 배리에이션 바이오테크놀로지스 아이엔씨. | Compositions and methods for treatment of cytomegalovirus |
-
2013
- 2013-10-30 KR KR1020157013906A patent/KR20150076244A/en not_active Application Discontinuation
- 2013-10-30 US US14/436,943 patent/US20150359879A1/en not_active Abandoned
- 2013-10-30 EP EP16189387.0A patent/EP3269388A1/en not_active Withdrawn
- 2013-10-30 SG SG11201501623PA patent/SG11201501623PA/en unknown
- 2013-10-30 JP JP2015540112A patent/JP6294890B2/en not_active Expired - Fee Related
- 2013-10-30 ES ES13789738.5T patent/ES2608637T3/en active Active
- 2013-10-30 CA CA2885145A patent/CA2885145A1/en not_active Abandoned
- 2013-10-30 MX MX2015005505A patent/MX2015005505A/en unknown
- 2013-10-30 RU RU2015121828A patent/RU2015121828A/en not_active Application Discontinuation
- 2013-10-30 WO PCT/EP2013/072717 patent/WO2014068001A1/en active Application Filing
- 2013-10-30 EP EP13789738.5A patent/EP2914284B1/en not_active Not-in-force
- 2013-10-30 CN CN201380057084.6A patent/CN104853772A/en active Pending
- 2013-10-30 AU AU2013340820A patent/AU2013340820A1/en not_active Abandoned
- 2013-10-30 BR BR112015008930A patent/BR112015008930A2/en not_active IP Right Cessation
-
2015
- 2015-03-16 IL IL237793A patent/IL237793A0/en unknown
- 2015-04-24 PH PH12015500931A patent/PH12015500931A1/en unknown
-
2016
- 2016-02-02 HK HK16101176.6A patent/HK1213185A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3269388A1 (en) | 2018-01-17 |
| JP2015536937A (en) | 2015-12-24 |
| BR112015008930A2 (en) | 2017-11-21 |
| IL237793A0 (en) | 2015-05-31 |
| EP2914284A1 (en) | 2015-09-09 |
| US20150359879A1 (en) | 2015-12-17 |
| AU2013340820A1 (en) | 2015-03-19 |
| ES2608637T3 (en) | 2017-04-12 |
| HK1213185A1 (en) | 2016-06-30 |
| CN104853772A (en) | 2015-08-19 |
| WO2014068001A1 (en) | 2014-05-08 |
| CA2885145A1 (en) | 2014-05-08 |
| PH12015500931A1 (en) | 2015-06-29 |
| MX2015005505A (en) | 2016-01-08 |
| KR20150076244A (en) | 2015-07-06 |
| RU2015121828A (en) | 2016-12-20 |
| EP2914284B1 (en) | 2016-09-21 |
| JP6294890B2 (en) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1213185A1 (en) | Recombinant particle based vaccines against human cytomegalovirus infection | |
| IL261204A (en) | Influenza virus vaccines and uses thereof | |
| HK1207967A1 (en) | Vaccine | |
| HK1209439A1 (en) | Interleukin-10 fusion proteins and uses thereof -10 | |
| EP2614072A4 (en) | Human cytomegalovirus vaccine | |
| EP2830692A4 (en) | Patient interface | |
| EP2820033A4 (en) | Interleukin-10 polypeptide conjugates and their uses | |
| EP2806891A4 (en) | Parainfluenza virus 5 based vaccines | |
| PL2935313T3 (en) | Vaccines against hepatitis b virus | |
| EP2909238A4 (en) | Improved human herpesvirus immunotherapy | |
| HK1204479A1 (en) | Expression and secretion system | |
| HK1210475A1 (en) | Herpes simplex virus vaccine | |
| EP3054994A4 (en) | Human papilloma virus therapeutic vaccine | |
| HK1212730A1 (en) | Ube2t peptides and vaccines containing the same ube2t | |
| IL229956B (en) | Mphosphi peptides and vaccines including the same | |
| EP2931176A4 (en) | Medical sling | |
| EP2678043A4 (en) | Recombinant mumps virus vaccine | |
| EP2919806A4 (en) | Gonorrheal mtre peptides and vaccines | |
| EP2822599A4 (en) | Vaccine formulation | |
| HK1201283A1 (en) | Influenza c virus and vaccine | |
| EP2839840A4 (en) | Recombinant trivalent vaccine against human influenza | |
| EP2891497A4 (en) | Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope | |
| GB201215184D0 (en) | Therapeutic virus | |
| HUE051050T2 (en) | Recombinant human igm-antibody effective against cancer cells | |
| EP2862873A4 (en) | IgE PEPTIDE VACCINE |